Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Swiss Exchange  >  Newron Pharmaceuticals SpA    NWRN   IT0004147952

NEWRON PHARMACEUTICALS SPA (NWRN)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
OFFRE ETE Zonebourse : Jusqu'à 6 mois offerts sur tous les portefeuilles
Business Summary
Logo Newron Pharmaceuticals SpA
Discovers and develops small molecule drugs

Newron Pharmaceuticals SpA is a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system.

Its products include Xadago for Parkinson's disease; sarizotan for patients with Rett syndrome; and ralfinamide for patients with rare pain indications.

The company was founded by Luca Benatti, Ruggero Fariello, and Patricia Salvati in 1999 and is headquartered in Bresso, Italy.

Number of employees : 23 persons.
Sales per Businesses
20162017Delta
CHF (in Million)%CHF (in Million)%
Licence Income3.3164.2%11.5878.5% +249.63%
Royalties1.8535.8%3.1721.5% +71.29%
Sales per Regions
20162017Delta
CHF (in Million)%CHF (in Million)%
Italy & United States5.16100%14.91101.1% +188.77%
Managers
NameAgeSinceTitle
Stefan Weber542005Chief Executive Officer, Director & IR Contact
Ulrich Köstlin, PhD662013Non-Executive Chairman
Roberto Galli-2002Vice President-Finance
Ravi Anand, MD612005Chief Medical Officer
Patrick J. Langlois, PhD732008Independent Non-Executive Director
Robert Leslie Holland MD, PhD632013Independent Non-Executive Director
Joseph Donald deBethizy, PhD672014Independent Non-Executive Director
Luca Benatti, PhD572014Independent Non-Executive Director
Marco Caremi612002Executive Vice President-Business Development
Dennis Dionne-2015Vice President-Commercial Affairs
Equities
Vote QuantityFloatCompany-owned sharesTotal Float
Share A 1 17,844,345 14,701,710 82.4% 0 0.0% 82.4%
Shareholders
NameEquities%
Investor AB 1,670,317 9.36%
Aviva Plc 1,258,251 7.05%
Gefim SpA 785,448 4.40%
Polar Capital LLP 398,525 2.23%
UBS AG (Investment Management) 321,949 1.80%
EFG Asset Management (UK) Ltd. 170,000 0.95%
Union Investment Privatfonds GmbH 149,140 0.84%
Credit Suisse Asset Management (Schweiz) AG 143,236 0.80%
Zürcher Kantonalbank (Investment Management) 134,520 0.75%
Aviva Investors Global Services Ltd. 109,421 0.61%
Company contact information
Newron Pharmaceuticals SpA
via Ludovico Ariosto 21
Bresso, Milan 20091

Phone : +39.02.610.3461
Fax : +39.02.610.34654
Web : www.newron.com
Connections : Newron Pharmaceuticals SpA
Constantia Flexibles Group GmbH
Italian Angels For Biotech
European School of Management & Technology GmbH
NOXXON Pharma AG
Universitätsklinikum Würzburg
Constantia Flexibles AG
The European Association for Bioindustries
PJL Consulting
DFC Langlois
Proterris, Inc.
Oxford Gene Technology IP Ltd.
EryDel SpA
Early Clinical Development Consulting Ltd.
Assobiotec
White City Consulting ApS
Hunter-Fleming Ltd.
© 2018 People , Fundamentals and Ownership